Julian Olalla

Marbella, AN, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Correction: Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Correction: Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Journal: PloS one

Published: July 24, 2026

Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges.

Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges.

Journal: The New England journal of medicine

Published: May 13, 2026

Beyond Surveillance Mutations: Long-Term Trends and Clinical Relevance of Transmitted HIV Drug Resistance in Spain (2007-2023).

Beyond Surveillance Mutations: Long-Term Trends and Clinical Relevance of Transmitted HIV Drug Resistance in Spain (2007-2023).

Journal: Open forum infectious diseases

Published: March 13, 2026

QR Code-Enabled Self-Access Lifestyle Education in Older People Living With HIV: Pragmatic Pilot Quasi-Experimental Pretest-Posttest Implementation Study.

QR Code-Enabled Self-Access Lifestyle Education in Older People Living With HIV: Pragmatic Pilot Quasi-Experimental Pretest-Posttest Implementation Study.

Journal: Journal of medical Internet research

Published: February 23, 2026

Circulating miRNA Signatures Associated with Atherosclerosis and Cardiometabolic Comorbidities in People with HIV.

Circulating miRNA Signatures Associated with Atherosclerosis and Cardiometabolic Comorbidities in People with HIV.

Journal: Medical sciences (Basel, Switzerland)

Published: January 11, 2026

Intensification with a CCR5 inhibitor at antiretroviral therapy initiation modulates interleukin-18 and inflammation-driven immune pathways in people with HIV.

Intensification with a CCR5 inhibitor at antiretroviral therapy initiation modulates interleukin-18 and inflammation-driven immune pathways in people with HIV.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: September 09, 2025

Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Journal: PloS one

Published: July 11, 2025

Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Journal: PloS one

Published: July 11, 2025

Prevalence of frailty in people living with HIV over 60 years old in southern Spain.

Prevalence of frailty in people living with HIV over 60 years old in southern Spain.

Journal: Medicine

Published: May 17, 2025

Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study.

Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study.

Journal: Viruses

Published: May 13, 2025

Transforming long-term care for people with HIV: Movimiento AHORA.

Transforming long-term care for people with HIV: Movimiento AHORA.

Journal: Enfermedades infecciosas y microbiologia clinica (English ed.)

Published: April 23, 2025

Exploring the acceptability, appropriateness, feasibility and satisfaction of an implementation strategy for out-of-HOspital administration of the Long-Acting combination of cabotegravir and rilpivirine as an optional therapy for HIV in Spain (the HOLA study)-a hybrid implementation-effectiveness, phase IV, double-arm, open-label, multicentric study: study protocol.

Exploring the acceptability, appropriateness, feasibility and satisfaction of an implementation strategy for out-of-HOspital administration of the Long-Acting combination of cabotegravir and rilpivirine as an optional therapy for HIV in Spain (the HOLA study)-a hybrid implementation-effectiveness, phase IV, double-arm, open-label, multicentric study: study protocol.

Journal: BMJ open

Published: April 11, 2025

Showing 1-12 of 55

Last Updated: 09/26/2026